Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
Completed
Callisto Pharmaceuticals
Phase 1/Phase 2
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and
to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Completed
Callisto Pharmaceuticals
Phase 2
This study will evaluate the safety and efficacy of atiprimod treatment in patients with low
to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable
local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing)
despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).
Study of Atiprimod Treatment for Patients With Advanced Cancer
Terminated
Callisto Pharmaceuticals
Phase 1
Primary Objectives:
The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to
evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360
mg/day, or the MTD, whichever is lower, in patients with advanced cancer.
Secondary Objectives:
The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and
to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to
compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the
intent of switching to capsules for the dose escalation if the capsules pose no safety
issues.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
